Canariabio Inc.

This phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …

This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix i…

This study tests whether adding oregovomab to the standard drug niraparib can help control recurrent ovarian cancer in 10 women whose cancer returned after initial platinum-based chemotherapy. The goal is to shrink or stabilize tumors for at least 12 to 24 weeks. This is not a cu…

This phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 615 participants who had surgery to remove as much cancer as po…